

Clanotech AB to present CLT-28643 in the treatment of eye disease at BioTrinity 2015 on 13 May 2015

Stockholm – May 12, 2015. Clanotech AB, today announced that it will present its lead compound CLT-28643 for the treatment of eye diseases at BioTrinity 2015, Europe's leading Biopartnering and Investment Conference, to be held on 11-13 May at the Novotel London West.

Dr Mario G Fsadni, acting CMO at Clanotech, is presenting CLT-28643, a novel $\alpha 5\beta 1$ integrin receptor antagonist for the treatment of eye diseases. The presentation will be included in the RegenMed/Other Therapies Showcase to be held on Wednesday 13th May 2015 from 13:30 till 17:30 during BioTrinity 2015.

Founded and produced by OBN, BioTrinity is now in its ninth year. BioTrinity has grown rapidly over recent years, and is now located in London to accommodate increased interest. More than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms are expected to meet one-on-one, attend panel discussions, company showcases and workshops, or browse the company showcases, seeking out their next deals.

Jon Rees, CEO of OBN, said: "BioTrinity has become the "must attend" life sciences conference for emerging European companies, investors and partners. We are excited to be hosting what we believe would be the great business development opportunity of 2015. This announcement from Clanotech AB confirms that this is an event that deal and decision makers cannot afford to miss."

ENDS

Contacts

Clanotech

Patrizia Caldirola, CEO, Clanotech AB

Tel: +46 70 374 7179,

Email: patrizia.caldirola@clanotech.com

Citigate Dewe Rogerson

Sylvie Berrebi

Tel: +44(0)20-7638-9571

Email: Sylvie.berrebi@citigatedr.co.uk

About Clanotech AB

Clanotech is a Swedish biotech company active in ophthalmology. Clanotech's development strategy spans from niche indications with orphan drug opportunities such as developing safe and target specific anti-scarring treatment in glaucoma surgery techniques to therapeutic areas with high commercial potential. Clanotech's lead candidate is an inhibitor of the $\alpha 5\beta 1$ -integrin receptor, which is present in

fibroblasts and on vascular endothelial cells. $\alpha 5\beta 1$ -integrin is strongly up-regulated in fibroblasts when switching to the fibrotic state and in scars after glaucoma surgery.

About OBN

OBN is the Membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 370-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is best known for its delivery of BioTrinity (May 11-13), Europe's leading life sciences investment and biopartnering conference.

Further information about OBN's tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN's website www.obn.org.uk.